Immutep's Efti in Combination with Pembrolizumab Achieves Ex

Media Release Immuno-oncology combination of eftilagimod alpha and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002... | May 17, 2023

Related Keywords

Sydney , New South Wales , Australia , London , City Of , United Kingdom , Canada , United States , University College , American , Australian , Chris Basta , Marc Voigt , Martin Forster , American Cancer Society , Drug Administration , Immutep Limited , Nasdaq , Data Monitoring Committee , University College London Hospital , Corporate Communications , Merck Co Inc , Society For Immunotherapy Of Cancer , Merck Sharp Dohme , Cancer Institute , Overall Survival , Proportion Score , Fast Track , Merck Sharp , Eftilagimod Alpha , Fast Track Designation , United States Food , Non Small Cell Lung Cancer , Neck Squamous Cell Carcinoma , Lymphocyte Activation , Investor Relations , Global Cancer Observatory , Lung Cancer Fact , Cancer Society , About Lung , Lung Cancer , Immutep Limited Stock Exchange , News , Information , Press Release , Media , Release , Combination , F , Ftilagimod , Lpha , End , The , Reading , Therapy , Generates , Meaningful , Survival , N , Fell , Young , Dancer , Patients , Hase , I Immp Us45257l1089 ,